An effective second-generation outer surface protein A-derived Lyme vaccine that eliminates a potentially autoreactive T cell epitope.

The antigenic component of a common Lyme disease vaccine is recombinant outer surface protein A (rOspA) of Borrelia burgdorferi (Bb), the causative agent of Lyme disease. Coincidentally, patients with chronic, treatment-resistant Lyme arthritis develop an immune response against OspA, whereas those with acute Lyme disease usually do not. Treatment-resistant Lyme arthritis occurs in a subset of Lyme arthritis patients and is linked to HLA.DRB1*0401 (DR4) and related alleles. Recent work from our laboratory identified T cell crossreactivity between epitopes of OspA and lymphocyte function-associated antigen 1alpha(L) chain (LFA-1alpha(L)) in these patients. We generated a form of rOspA, FTK-OspA, in which the LFA-1alpha(L)/rOspA crossreactive T cell epitope was mutated to reduce the possible risk of autoimmunity in genetically susceptible individuals. FTK-OspA did not stimulate human or mouse DR4-restricted, WT-OspA-specific T cells, whereas it did stimulate antibody responses specific for WT-OspA that were similar to mice vaccinated WT-OspA. We show here that the protective efficacy of FTK-OspA is indistinguishable from that of WT-OspA in vaccination trials, as both C3H/HeJ and BALB/c FTK-OspA-vaccinated mice were protected from Bb infection. These data demonstrate that this rOspA-derived vaccine lacking the predicted cross-reactive T cell epitope, but retaining the capacity to elicit antibodies against infection, is effective in generating protective immunity.

[1]  J. Ohnishi,et al.  Antigenic and genetic heterogeneity of Borrelia burgdorferi populations transmitted by ticks. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[2]  A. Steere,et al.  The clinical evolution of Lyme arthritis. , 1987, Annals of internal medicine.

[3]  U. Schaible,et al.  Experimental Borrelia burgdorferi infection in inbred mouse strains: Antibody response and association of H‐2 genes with resistance and susceptibility to development of arthritis , 1991, European journal of immunology.

[4]  M. Kramer,et al.  Plasmid DNA and protein vaccination of mice to the outer surface protein A of Borrelia burgdorferi leads to induction of T helper cells with specificity for a major epitope and augmentation of protective IgG antibodies in vivo , 1996, European journal of immunology.

[5]  B. P. Guo,et al.  Resistance to Lyme disease in decorin-deficient mice. , 2001, The Journal of clinical investigation.

[6]  D. Parenti,et al.  Immunogenicity of a recombinant Borrelia burgdorferi outer surface protein A vaccine against Lyme disease in children. , 1999, The Journal of pediatrics.

[7]  A. Steere,et al.  Chronic Lyme arthritis. Clinical and immunogenetic differentiation from rheumatoid arthritis. , 1979, Annals of internal medicine.

[8]  A. Steere,et al.  Molecular Mimicry in Lyme Arthritis Demonstrated at the Single Cell Level: LFA-1αL Is a Partial Agonist for Outer Surface Protein A-Reactive T Cells1 , 2001, The Journal of Immunology.

[9]  E. Fikrig,et al.  Borrelia burgdorferi P35 and P37 proteins, expressed in vivo, elicit protective immunity. , 1997, Immunity.

[10]  A. Steere,et al.  Autoimmune mechanisms in antibiotic treatment-resistant lyme arthritis. , 2001, Journal of autoimmunity.

[11]  J. Piffaretti,et al.  Association between different clinical manifestations of Lyme disease and different species of Borrelia burgdorferi sensu lato. , 1995, Research in microbiology.

[12]  J. Weis,et al.  Rapid and Sensitive Quantification ofBorrelia burgdorferi-Infected Mouse Tissues by Continuous Fluorescent Monitoring of PCR , 1999, Journal of Clinical Microbiology.

[13]  C. Schmid,et al.  Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group. , 1998, The New England journal of medicine.

[14]  F. Falcioni,et al.  HLA-DR4-IE chimeric class II transgenic, murine class II-deficient mice are susceptible to experimental allergic encephalomyelitis , 1996, The Journal of experimental medicine.

[15]  S. Malawista,et al.  A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. Recombinant Outer-Surface Protein A Lyme Disease Vaccine Study Consortium. , 1998, The New England journal of medicine.

[16]  E. Fikrig,et al.  Molecular Adaptation of Borrelia burgdorferi in the Murine Host , 2002, The Journal of experimental medicine.

[17]  V. Sikand,et al.  Safety and immunogenicity of a recombinant Borrelia burgdorferi outer surface protein A vaccine against lyme disease in healthy children and adolescents: a randomized controlled trial. , 2001, Pediatrics.

[18]  A. Steere,et al.  The clinical spectrum and treatment of Lyme disease. , 1984, The Yale journal of biology and medicine.

[19]  M. Hanson,et al.  Evidence for Vaccine Synergy between Borrelia burgdorferi Decorin Binding Protein A and Outer Surface Protein A in the Mouse Model of Lyme Borreliosis , 2000, Infection and Immunity.

[20]  Robert T. Chen,et al.  Adverse event reports following vaccination for Lyme disease: December 1998-July 2000. , 2002, Vaccine.

[21]  B. P. Guo,et al.  Active and Passive Immunity against Borrelia burgdorferi Decorin Binding Protein A (DbpA) Protects against Infection , 1998, Infection and Immunity.

[22]  Y. Lobet,et al.  Evaluation of the safety, reactogenicity and immunogenicity of three recombinant outer surface protein (OspA) lyme vaccines in healthy adults. , 1996, Vaccine.

[23]  A. Steere,et al.  Early and late antibody responses to full-length and truncated constructs of outer surface protein A of Borrelia burgdorferi in Lyme disease , 1995, Infection and immunity.

[24]  A. Steere,et al.  Binding of outer surface protein A and human lymphocyte function-associated antigen 1 peptides to HLA-DR molecules associated with antibiotic treatment-resistant Lyme arthritis. , 2003, Arthritis and rheumatism.

[25]  Y. Lobet,et al.  Reactivity with a specific epitope of outer surface protein A predicts protection from infection with the Lyme disease spirochete, Borrelia burgdorferi , 1997, Infection and immunity.

[26]  G. Maupin,et al.  Assessing the prevention effectiveness of local Lyme disease control. , 1999, Journal of public health management and practice : JPHMP.

[27]  W. N. Kelley,et al.  Textbook of Internal Medicine , 1989 .

[28]  D F Stroup,et al.  Occupational Risk of Lyme Disease in Endemic Areas of New York State , 1988, Annals of the New York Academy of Sciences.

[29]  A. Steere,et al.  ASSOCIATION OF CHRONIC LYME ARTHRITIS WITH HLA‐DR4 and HLA‐DR2 ALLELES , 1990, The New England journal of medicine.

[30]  A. Steere,et al.  Direct enumeration of Borrelia-reactive CD4 T cells ex vivo by using MHC class II tetramers. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[31]  W. Todd,et al.  Lyme disease spirochetes and ixodid tick spirochetes share a common surface antigenic determinant defined by a monoclonal antibody , 1983, Infection and immunity.

[32]  J. Dunn,et al.  Outer surface protein A (OspA) from the Lyme disease spirochete, Borrelia burgdorferi: high level expression and purification of a soluble recombinant form of OspA. , 1990, Protein expression and purification.

[33]  T Hoshi,et al.  Biophysical and molecular mechanisms of Shaker potassium channel inactivation , 1990, Science.

[34]  C. Rosé,et al.  Arthritis following recombinant outer surface protein A vaccination for Lyme disease. , 2001, The Journal of rheumatology.

[35]  A. Steere,et al.  T helper 1 response is dominant and localized to the synovial fluid in patients with Lyme arthritis. , 1998, Journal of immunology.

[36]  E. Fikrig,et al.  Inability of truncated recombinant Osp A proteins to elicit protective immunity to Borrelia burgdorferi in mice. , 1993, Journal of immunology.

[37]  A. Steere,et al.  Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis. , 1998, Science.

[38]  A. Steere,et al.  Association of treatment-resistant chronic Lyme arthritis with HLA-DR4 and antibody reactivity to OspA and OspB of Borrelia burgdorferi , 1993, Infection and immunity.

[39]  E. Fikrig,et al.  Borrelia burgdorferi Gene Expression In Vivo and Spirochete Pathogenicity , 2000, Infection and Immunity.

[40]  Z. Nagy,et al.  Precise prediction of major histocompatibility complex class II-peptide interaction based on peptide side chain scanning , 1994, The Journal of experimental medicine.

[41]  E. Fikrig,et al.  A monoclonal antibody to OspA inhibits association of Borrelia burgdorferi with human endothelial cells , 1993 .

[42]  A. Frey,et al.  Protection against tick-transmitted Lyme disease in dogs vaccinated with a multiantigenic vaccine. , 2001, Vaccine.

[43]  C H Schmid,et al.  Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. , 2001, The New England journal of medicine.

[44]  E. Fikrig,et al.  Elimination of Borrelia burgdorferi from vector ticks feeding on OspA-immunized mice. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[45]  M. Kramer,et al.  Therapeutic passive vaccination against chronic Lyme disease in mice. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[46]  H. Müller-Hermelink,et al.  Recombinant outer surface protein a from Borrelia burgdorferi induces antibodies protective against spirochetal infection in mice. , 1991, The Journal of infectious diseases.

[47]  A. Steere,et al.  The spirochetal etiology of Lyme disease. , 1983, The New England journal of medicine.

[48]  Haiyang Li,et al.  Crystal structure of Lyme disease antigen outer surface protein A complexed with an Fab. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[49]  A. Barbour,et al.  Experimental immunization against Lyme borreliosis with recombinant Osp proteins: An overview , 1996, Infection.

[50]  B. Luft,et al.  Human T lymphocyte response to Borrelia burgdorferi infection: no correlation between human leukocyte function antigen type 1 peptide response and clinical status. , 2003, The Journal of infectious diseases.

[51]  Maria Labandeira-Rey,et al.  VraA (BBI16) Protein of Borrelia burgdorferi Is a Surface-Exposed Antigen with a Repetitive Motif That Confers Partial Protection against Experimental Lyme Borreliosis , 2001, Infection and Immunity.

[52]  E. Fikrig,et al.  Borrelia burgdorferi OspA is an arthropod-specific transmission- blocking Lyme disease vaccine , 1996, The Journal of experimental medicine.